David R. Epstein, Director at Rubius Therapeutics, Inc. (RUBY), bought 30,000 shares at $1.44 ($43K) on 2022-04-21, disclosed to the SEC on 2022-04-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| TEM | SELL | 2026-06-03 | $12K | — | Filing → |
| TEM | SELL | 2026-03-04 | $13K | — | Filing → |
| TEM | SELL | 2026-02-04 | $22K | — | Filing → |